MedTrace Logo

Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure

NCT00941681 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2013-02-12

Study results available
· View outcomes & findings →

Summary

This study is designed to understand the pharmacokinetics of different oral formulations of CK-1827452 being considered for future studies in patients with heart failure. This study will compare the pharmacokinetics and safety and tolerability of both modified-release (MR) and immediate-release (IR) oral formulations of CK-1827452.

Conditions

Interventions

DRUG

CK-1827452

50 mg MR CK-1827452 BID for 10 days

DRUG

CK-1827452

37.5 mg IR CK-1827452 TID for 10 days

DRUG

CK-1827452

100 mg MR CK-1827452 BID for 10 days

Sponsors & Collaborators

  • Cytokinetics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • Georgia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00941681 on ClinicalTrials.gov